Related Experiment Video
Updated: Jul 16, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Should cholesterol-lowering medications be available in Canada without a prescription?
1Department of Cardiology, McGill University, Montreal, Quebec. shirya2004@yahoo.ca
Insights
Many Canadians with elevated cholesterol are undertreated for cardiovascular disease (CVD) risk. Over-the-counter (OTC) or behind-the-counter (BTC) statins could address this gap for moderate-risk individuals.
Area of Science:
- Public Health
- Cardiology
- Pharmacology
Background:
- Cardiovascular disease (CVD) poses a significant and increasing burden on Canadian healthcare.
- Elevated low-density lipoprotein cholesterol (LDL-C) is a primary risk factor for premature CVD.
- Statins effectively reduce LDL-C and CVD risk, yet a treatment gap exists.
Purpose of the Study:
- To explore the potential of over-the-counter (OTC) or behind-the-counter (BTC) statins for primary prevention in Canada.
- To identify undertreated populations, specifically those at moderate risk for CVD.
Main Methods:
- Literature review on statin efficacy and current treatment gaps.
- Analysis of the potential for OTC/BTC statin introduction in Canada.
- Consideration of hypercholesterolemia management and patient consultation.
Main Results:
- Moderate-risk individuals with elevated cholesterol are currently undertreated.
- OTC/BTC statins may offer a primary prevention strategy for this group.
- Careful consideration of risks and benefits is essential.
Conclusions:
- Addressing the statin treatment gap is crucial for CVD prevention in Canada.
- OTC/BTC statins present a potential solution for moderate-risk individuals.
- Further evaluation of OTC/BTC statin implementation is required, emphasizing patient consultation.
Abstract:
Cardiovascular disease (CVD) presents an enormous and growing burden on the Canadian health care system. Elevated serum low-density lipoprotein cholesterol levels are an established, major risk factor in the development of premature CVD. There is strong evidence that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, or statins, significantly lower both low-density lipoprotein cholesterol levels and CVD risk. However, there is currently a treatment gap, in that a large segment of the population who should be receiving statins due to elevated serum cholesterol levels are not. Individuals at moderate risk of developing CVD represent one large population segment that is currently being undertreated. This group may be a candidate for receiving over-the-counter (OTC) or behind-the-counter (BTC) statins, which may be a suitable primary prevention strategy. Nonetheless, it must be noted that hypercholesterolemia is a complex, chronic condition that must be carefully managed and requires close consultation with a health care practitioner. The advantages and disadvantages of OTC or BTC statin usage must therefore be carefully weighed before any potential introduction of OTC or BTC statins in Canada.
More Related Videos
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Coronary Artery Disease IV: Preventive Measures
Lipids: Dietary Sources and Requirements
Cholesterol: Significance and Regulation
Considering cholesterol and...
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
